Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DSGN vs MGTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGTX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

MGTX Overall Winner 6-Pillar Tally: DSGN 0 – 6 MGTX Matrix Metrics: DSGN 3 – 7 MGTX

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas MGTX carries 48.0/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin).

  • Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. MGTX 48.0/100 HOLD), MGTX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DSGN vs MGTX
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $10.53 · SMA50: $11.59
MGTX NASDAQ Head-to-Head Winner
MeiraGTx Holdings plc Ordinary Shares
Biological Products, (No Disgnostic Substances)
$8.85
-3.59% 1D
Market Cap $844.2M
TTM Revenue $398M
Forward P/E 64.1x
Beta / 30D Vol 1.65β · 68% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 48.0 Fund 57.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.7%), weak momentum, RSI 41
RSI-14: 41.5 · SMA20: $9.39 · SMA50: $10.61

6-Pillar Scorecard Institutional Category Breakdown (DSGN 0 – 6 MGTX)

Columns: Metric · DSGN · MGTX
1. Valuation Multiples MGTX
Forward P/E N/M 64.1x
Trailing P/E N/M 10.1x
PEG Ratio N/M N/M
EV / Revenue N/M 2.0x
2. Growth & Scale MGTX
Revenue Growth (YoY) +0.0% +8608.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $33,000 $398M
Market Cap $677.5M $844.2M
3. Profitability & Quality MGTX
Gross Margin N/A 97.9%
Operating Margin 0.0% 46.3%
Net Profit Margin 0.0% 19.9%
Return on Equity (ROE) -36.9% 72.2%
4. Balance Sheet & Cash Flow MGTX
Cash Generation (TTM) -$59M -$28M
Cash Flow Margin N/A -7.0%
Net Cash / Leverage $13M Net Cash $51M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MGTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 92.0% (13th %ile) 52.9% (3rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat MGTX
OpEx & R&D Intensity N/A 51.6% of Rev ($205M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DSGN (3) vs MGTX (7)
Institutional Metric DSGN MGTX Criterion Row Edge
Market Capitalization
Scale
$677.5M $844.2M Larger Scale MGTX
Trailing P/E Ratio
Valuation
N/M 10.1x Lower Multiple MGTX
Forward P/E Ratio
Valuation
N/M 64.1x Lower Multiple MGTX
Revenue Growth (YoY)
Growth
+0.0% +8608.6% Higher Growth MGTX
Operating Margin (TTM)
Profitability
0.0% 46.3% Higher Margin MGTX
Net Profit Margin
Profitability
0.0% 19.9% Higher Margin MGTX
Return on Equity (ROE)
Capital Efficiency
-36.9% 72.2% Higher ROE MGTX
52-Week Range Position
Momentum
30% ($7–$17) 26% ($7–$15) Stronger Trend DSGN
Beta / 30D Volatility
Risk Regime
1.32β · 61% Vol 1.65β · 68% Vol Lower Realized Risk DSGN
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite DSGN
Trailing 12M Revenue (USD)
Operating Scale
$33,000 $398M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 97.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$59M ($13M Net Cash) -$28M ($51M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DSGN +1.04 pp
DSGN: -3.59% · MGTX: -4.63%
3M Horizon DSGN +1.38 pp
DSGN: -34.91% · MGTX: -36.29%
6M Horizon MGTX +1.25 pp
DSGN: -7.1% · MGTX: -5.85%
1Y Horizon DSGN +33.65 pp
DSGN: +40.79% · MGTX: +7.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DSGN Revenue MGTX Revenue DSGN Op. Margin MGTX Op. Margin Margin Leader
FY2019 N/A $10M N/A -438.4% MGTX
FY2020 $0M $20M -3685.8% -401.9% MGTX
FY2021 N/A $40M N/A -193.0% MGTX
FY2022 N/A $20M N/A -730.9% MGTX
FY2023 N/A $10M N/A -977.8% MGTX
FY2024 N/A $30M N/A -493.4% MGTX
FY2025 N/A $80M N/A -130.2% MGTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MGTX BREAKDOWN
62d in phase · OBV ACCUMULATION
Current IV 52.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MGTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MGTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $844.2M market capitalization and 46.3% operating margin.
OpEx & R&D Reinvestment 51.6% of Rev ($205M)
90D Engineering Disclosures 0 Published

Investor FAQ DSGN vs MGTX Key Questions & Quantitative Answers

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas MGTX carries 48.0/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin). Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. MGTX 48.0/100 HOLD), MGTX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY). Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile MGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MGTX leads the Growth & Scale pillar: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with MGTX at +8608.6% YoY revenue growth and +0.0% YoY earnings growth on $398M TTM revenue (97.9% gross margin, 46.3% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), DSGN cumulative revenue shifted N/A while MGTX shifted +700.0%. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus 51.6% of Rev ($205M) (0 disclosures) for MGTX.

MGTX screens cheaper on headline valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MGTX trades at 64.1x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (-7.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus MGTX (72.2% ROE) capital efficiency.

In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, MGTX carries 52.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.